Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
GlobalData on MSN1d
Palatin’s UC therapy prompts clinical remission in a third of patientsA third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
Body mass index did not impact the safety and efficacy of etrasimod in patients with ulcerative colitis, according to 2 studies.
Endoscopic remission was achieved by 19.5% ... noting that infliximab is generally considered a stronger treatment for ulcerative colitis, especially when used with combination immunosuppressant ...
ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...
Johnson & Johnson said that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative colitis, met main goal.
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
Endoscopic remission at week 14 was achieved ... combination therapy that is administered in ulcerative colitis, said Allez, who was the session’s co-chair. This is a “key aspect” as ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Pharmaceutical Technology on MSN9d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback